Navigation Links
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results
Date:8/11/2011

), October 16-19, in Pittsburg, Pa.
  • American College of Surgeons (ACS), October 23-27, in San Francisco, Calif.

  • Today's Conference Call and Webcast ReminderThe Pacira management team will host a conference call discussing the company's second quarter financial results, recent developments and 2011 financial guidance today at 9 a.m. (EDT). The call can be accessed by dialing 1-800-884-5695 (domestic) or 1-617-786-2960 (international) five minutes prior to the start of the call and providing the passcode 37821534. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 61411246. The replay of the call will be available for two weeks from the date of the live call.

    The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Pacira's website at www.pacira.com. A replay of the webcast will be archived on the company's website for two weeks following the call.

    About PaciraPacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postsurgical analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, whic
    '/>"/>

    SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
    2. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
    3. Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
    4. Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
    5. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
    6. Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference
    7. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
    8. Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
    9. Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
    10. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
    11. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/2/2014)... , Oct. 2, 2014   Mast Therapeutics, ... announced today that Edwin L. Parsley , D.O. ... and Senior Vice President.  Dr. Parsley has ... Aires Pharmaceuticals, Inc. in February 2014.  He has served ... and as Chief Medical Officer of Aires since April ...
    (Date:10/2/2014)...   Intarcia Therapeutics, Inc. today announced successful ... clinical trials for ITCA 650 (exenatide, delivered continuously once ... The first trial, FREEDOM-1, was a placebo-controlled, double-blind phase ... of ITCA 650 in patients with type 2 diabetes ... significantly superior to placebo for both 40 mcg and ...
    (Date:10/1/2014)...   Plexus Information Systems, Inc. (Plexus ... Systems (AIMS), announced a partnership with NextGen ... subsidiary of Quality Systems, Inc. and a leading ... Logo - http://photos.prnewswire.com/prnh/20140930/149406 ... This partnership extends the NextGen Healthcare product portfolio ...
    Breaking Medicine Technology:Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
    ... Feb. 9, 2011 Reportlinker.com announces that ... in its catalogue: Global ... Plaque Treatment 2011 ... the responses of a comprehensive survey conducted ...
    ... 9, 2011 Reportlinker.com announces that a new ... Asia Pacific Markets for Orthopedic ... http://www.reportlinker.com/p0377965/Asia-Pacific-Markets-for-Orthopedic-Large-Joint-Reconstructive-Devices-2011.html In 2010, the ... Japan and South Korea were valued at over ...
    Cached Medicine Technology:Reportlinker Adds Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011 2Reportlinker Adds Asia Pacific Markets for Orthopedic Large Joint Reconstructive Devices 2011 2
    (Date:10/2/2014)... 1, 2014 (HealthDay News) -- Genes may interact with stress ... suggests. The genetic risk occurs in about 13 percent ... finding could help these people reduce their heart disease risk ... and stress management, the Duke University researchers said. The ... found a strong link between variations in the EBF1 gene ...
    (Date:10/2/2014)... By Dennis Thompson ... -- A newborn,s risk of developing celiac disease isn,t reduced ... found in wheat called gluten to an infant,s diet help ... a pair of new studies in the Oct. 2 ... put to rest hopes that a child could avoid celiac ...
    (Date:10/2/2014)... Dennis Thompson HealthDay ... Forty-two states and the District of Columbia now have a ... respiratory illness that has been infecting children since the ... with the virus have died in recent weeks, but it,s ... played in those deaths, officials said. Health officials are ...
    (Date:10/1/2014)... small protein beta-amyloid is strongly associated with Alzheimer,s disease; ... this peptide is the causal agent of the onset ... such confirmation is that beta-amyloid is not harmful when ... is when it self-assembles to form the so-called amyloid ... target, beta-amyloid alone, but with multiple ones because each ...
    (Date:10/1/2014)... human eye, the brain of a rat and a ... says a QUT leading robotics researcher. , Dr ... the new study uses new computer algorithms to enable ... tunnels. , "This is a very Frankenstein type of ... of a thing together because we,re taking the eyes ...
    Breaking Medicine News(10 mins):Health News:Genes May Make Some More Prone to Heart Disease When Under Stress 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2
    ... LeMond ... real-to-life road feel and performance output to ensure avid cyclists and triathletes stay in ... ... introduces the all-new Revolution bike trainer that delivers the industry,s most real-to-life ...
    ... ... get more exposure through free publicity and other low cost PR methods. , ... (PRWEB) July 2, 2010 -- ADPublishing.org LLC, ... guide which enables small business owners to generate their own free publicity. Online PR and ...
    ... ... C-rich , ... IL (PRWEB) July 2, 2010 -- There’s growing consumer awareness and concern in the U.S. ... children. This month (July 2010), European food and beverage manufacturers will be required to include ...
    ... routine for protection against infection when percutaneous endoscopic gastrostomy ... wall, is surgically inserted in the stomach. The new ... used today. The method, presented in the British ... 200 patients at the Karolinska University Hospital in Solna, ...
    ... ... Northwestern Health Sciences University to create an experienced team of chiropractic and medical professionals ... years old). , ... (PRWEB) July 2, 2010 -- University of Western States has partnered with Northwestern Health ...
    ... ... Templar cross architecture contains math codes that support frequency-based medicine. The idea ... paradigm that will change the face of future medicine. , ... (PRWEB) July 2, 2010 -- It usually ...
    Cached Medicine News:Health News:As Real as It Gets: All-New LeMond Revolution Bike Trainer Delivers Incomparable Road Feel and Performance 2Health News:As Real as It Gets: All-New LeMond Revolution Bike Trainer Delivers Incomparable Road Feel and Performance 3Health News:Publishing and Media Distribution Firm Launches Online Public Relations Kit for Businesses Seeking Free Publicity 2Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 2Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 3Health News:Surf Sweets Among Few Candy Offerings Free of Synthetic Dyes Despite Growing Consumer Concern Over Affect on Children 4Health News:Simpler and cheaper antibiotic prophylaxis with insertion of nutrition catheter in the stomach 2Health News:Study Seeks Effective Treatment for Adolescent Low Back Pain 2Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 2Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 3Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 4Health News:Is Frequency the Future of Medicine or an Ancient Mystery Revealed? 5
    ... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
    ... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
    ... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
    ... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
    Medicine Products: